Mobile

A 52-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-013256-69

A 52-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium (18 μg o.d.) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary disease (COPD)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that QVA149 (110/50 μg o.d.) is superior to NVA237 (50 μg o.d.) with regard to the rate of moderate to severe COPD exacerbations during 52 weeks of treatment.

Critère d'inclusion

  • Chronic Obstructive Pulmonary Disease (COPD)

Liens